Get started
Adverum Biotechnologies, Inc.Adverum Biotechnologies, Inc.Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

ADVM chart


Full chart

ADVM upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪61.21 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−5.65 USD
Net income (FY)
‪−130.93 M‬ USD
Revenue (FY)
‪1.00 M‬ USD
Shares float
‪13.92 M‬
Beta (1Y)
1.07

Employees


Employees (FY)
155
Change (1Y)
+34 +28.10%
Revenue / Employee (1Y)
‪6.45 K‬ USD
Net income / Employee (1Y)
‪−844.69 K‬ USD

About Adverum Biotechnologies, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Laurent Fischer
Website
adverum.com
Headquarters
Redwood City
Founded
2006
FIGI
BBG006D9MR17
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ADVM news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as ADVM.

Frequently Asked Questions


The current price of ADVM is 2.92 USD — it has decreased by −6.83% in the past 24 hours. Watch Adverum Biotechnologies, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Adverum Biotechnologies, Inc. stocks are traded under the ticker ADVM.
ADVM stock has fallen by −20.41% compared to the previous week, the month change is a −51.34% fall, over the last year Adverum Biotechnologies, Inc. has showed a −74.32% decrease.
We've gathered analysts' opinions on Adverum Biotechnologies, Inc. future price: according to them, ADVM price has a max estimate of 33.00 USD and a min estimate of 5.00 USD. Watch ADVM chart and read a more detailed Adverum Biotechnologies, Inc. stock forecast: see what analysts think of Adverum Biotechnologies, Inc. and suggest that you do with its stocks.
ADVM reached its all-time high on Jan 8, 2015 with the price of 624.80 USD, and its all-time low was 2.75 USD and was reached on Apr 17, 2025. View more price dynamics on ADVM chart.
See other stocks reaching their highest and lowest prices.
ADVM stock is 6.93% volatile and has beta coefficient of 1.07. Track Adverum Biotechnologies, Inc. stock price on the chart and check out the list of the most volatile stocks — is Adverum Biotechnologies, Inc. there?
Today Adverum Biotechnologies, Inc. has the market capitalization of ‪57.03 M‬, it has decreased by −9.78% over the last week.
Yes, you can track Adverum Biotechnologies, Inc. financials in yearly and quarterly reports right on TradingView.
Adverum Biotechnologies, Inc. is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
ADVM earnings for the last quarter are −1.96 USD per share, whereas the estimation was −1.34 USD resulting in a −46.29% surprise. The estimated earnings for the next quarter are −1.94 USD per share. See more details about Adverum Biotechnologies, Inc. earnings.
Adverum Biotechnologies, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ADVM net income for the last quarter is ‪−40.93 M‬ USD, while the quarter before that showed ‪−27.13 M‬ USD of net income which accounts for −50.85% change. Track more Adverum Biotechnologies, Inc. financial stats to get the full picture.
No, ADVM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 22, 2025, the company has 155 employees. See our rating of the largest employees — is Adverum Biotechnologies, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Adverum Biotechnologies, Inc. EBITDA is ‪−129.91 M‬ USD, and current EBITDA margin is ‪−14.95 K‬%. See more stats in Adverum Biotechnologies, Inc. financial statements.
Like other stocks, ADVM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Adverum Biotechnologies, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Adverum Biotechnologies, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Adverum Biotechnologies, Inc. stock shows the sell signal. See more of Adverum Biotechnologies, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.